Earlier this year, FDA granted a breakthrough device designation for Orchestra BioMed’s Virtue sirolimus-eluting balloon (SEB) in the treatment of below-the-knee peripheral artery disease. The designation came just a few months after the New Hope, PA-based company announced its partnership with Terumo. The agreement included a $30 million up-front payment to Orchestra plus an equity commitment of $5 million.